KAIROS PHARMA LTD (KAPA) Fundamental Analysis & Valuation

NYSEARCA:KAPA • US48301N1046

Current stock price

0.5499 USD
-0.03 (-5.09%)
At close:
0.54 USD
-0.01 (-1.8%)
After Hours:

This KAPA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. KAPA Profitability Analysis

1.1 Basic Checks

  • KAPA had negative earnings in the past year.
  • In the past year KAPA has reported a negative cash flow from operations.
KAPA Yearly Net Income VS EBIT VS OCF VS FCFKAPA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 -1M -2M -3M

1.2 Ratios

  • KAPA has a worse Return On Assets (-62.76%) than 60.35% of its industry peers.
  • KAPA's Return On Equity of -66.05% is in line compared to the rest of the industry. KAPA outperforms 55.32% of its industry peers.
Industry RankSector Rank
ROA -62.76%
ROE -66.05%
ROIC N/A
ROA(3y)-111.42%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KAPA Yearly ROA, ROE, ROICKAPA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 100 -100 -200

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for KAPA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KAPA Yearly Profit, Operating, Gross MarginsKAPA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. KAPA Health Analysis

2.1 Basic Checks

  • KAPA has more shares outstanding than it did 1 year ago.
  • KAPA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
KAPA Yearly Shares OutstandingKAPA Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 2M 4M 6M 8M 10M
KAPA Yearly Total Debt VS Total AssetsKAPA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 1M 2M 3M 4M 5M

2.2 Solvency

  • An Altman-Z score of 13.55 indicates that KAPA is not in any danger for bankruptcy at the moment.
  • KAPA has a Altman-Z score of 13.55. This is amongst the best in the industry. KAPA outperforms 85.88% of its industry peers.
  • KAPA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 13.55
ROIC/WACCN/A
WACCN/A
KAPA Yearly LT Debt VS Equity VS FCFKAPA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 2M -2M 4M

2.3 Liquidity

  • A Current Ratio of 16.56 indicates that KAPA has no problem at all paying its short term obligations.
  • With an excellent Current ratio value of 16.56, KAPA belongs to the best of the industry, outperforming 94.00% of the companies in the same industry.
  • KAPA has a Quick Ratio of 16.56. This indicates that KAPA is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of KAPA (16.56) is better than 94.00% of its industry peers.
Industry RankSector Rank
Current Ratio 16.56
Quick Ratio 16.56
KAPA Yearly Current Assets VS Current LiabilitesKAPA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 1M 2M 3M 4M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. KAPA Growth Analysis

3.1 Past

  • The earnings per share for KAPA have decreased strongly by -33.55% in the last year.
EPS 1Y (TTM)-33.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to decrease by -13.70% on average over the next years. This is quite bad
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-31.67%
EPS Next 2Y-28.45%
EPS Next 3Y-31.68%
EPS Next 5Y-13.7%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KAPA Yearly Revenue VS EstimatesKAPA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2030 2031 2032 2033 200M 400M 600M 800M
KAPA Yearly EPS VS EstimatesKAPA Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 4 6

More info and screens

Find the best growth stocksShow best growing peers

0

4. KAPA Valuation Analysis

4.1 Price/Earnings Ratio

  • KAPA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year KAPA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KAPA Price Earnings VS Forward Price EarningsKAPA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KAPA Per share dataKAPA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2

4.3 Compensation for Growth

  • A cheap valuation may be justified as KAPA's earnings are expected to decrease with -31.68% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-28.45%
EPS Next 3Y-31.68%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. KAPA Dividend Analysis

5.1 Amount

  • KAPA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

KAPA Fundamentals: All Metrics, Ratios and Statistics

KAIROS PHARMA LTD

NYSEARCA:KAPA (3/30/2026, 8:12:42 PM)

After market: 0.54 -0.01 (-1.8%)

0.5499

-0.03 (-5.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14
Earnings (Next)N/A
Inst Owners4.11%
Inst Owner Change92.33%
Ins Owners36.18%
Ins Owner Change0%
Market Cap11.45M
Revenue(TTM)N/A
Net Income(TTM)-5.06M
Analysts82.22
Price Target8.5 (1445.74%)
Short Float %10.52%
Short Ratio2.04
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-22.77%
Min EPS beat(2)-42.6%
Max EPS beat(2)-2.94%
EPS beat(4)0
Avg EPS beat(4)-56.62%
Min EPS beat(4)-124.09%
Max EPS beat(4)-2.94%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.49
P/tB 1.51
EV/EBITDA N/A
EPS(TTM)-0.31
EYN/A
EPS(NY)-0.34
Fwd EYN/A
FCF(TTM)-0.2
FCFYN/A
OCF(TTM)-0.2
OCFYN/A
SpS0
BVpS0.37
TBVpS0.36
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -62.76%
ROE -66.05%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-111.42%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 16.56
Quick Ratio 16.56
Altman-Z 13.55
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-33.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30%
EPS Next Y-31.67%
EPS Next 2Y-28.45%
EPS Next 3Y-31.68%
EPS Next 5Y-13.7%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-175.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-677.2%
EBIT Next 3Y-180.07%
EBIT Next 5Y-129.35%
FCF growth 1Y-4982.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-4982.72%
OCF growth 3YN/A
OCF growth 5YN/A

KAIROS PHARMA LTD / KAPA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of KAIROS PHARMA LTD (KAPA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to KAPA.


What is the valuation status of KAIROS PHARMA LTD (KAPA) stock?

ChartMill assigns a valuation rating of 0 / 10 to KAIROS PHARMA LTD (KAPA). This can be considered as Overvalued.


How profitable is KAIROS PHARMA LTD (KAPA) stock?

KAIROS PHARMA LTD (KAPA) has a profitability rating of 0 / 10.


Can you provide the financial health for KAPA stock?

The financial health rating of KAIROS PHARMA LTD (KAPA) is 8 / 10.